Our ability to add value to in-licensed projects is founded on the drug development expertise of our team who have extensive experience in the key decision-making activities of early drug development.

Where appropriate, this expertise is complemented by the specific skills of external consultants and advisers with backgrounds in the biotechnology and pharmaceutical industries.

At Modern Biosciences, program management starts before we in-license an asset. We work closely with the inventors to create an efficient development program that achieves commercial proof-of-concept as rapidly as possible.

Each program is managed by one of our experienced asset managers, who is responsible for coordinating the activities of research institutions and the contract research organisations to which we outsource much of the early development work.

Where possible, we seek to run clinical trials that will generate early proof-of-mechanism and/or proof-of-principle, either through direct testing in patients and/or via the monitoring of biomarkers and surrogate markers of efficacy.